Supercharged immune cells take on melanoma in new combo therapy trial

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 53 adults aged 18 to 72 who have already tried at least one other treatment will take part. The approach involves removing some tumor tissue, growing immune cells from it in a lab, and returning them to the patient along with chemotherapy and other supportive drugs.